A multiscale mathematical model for oncolytic virotherapy.
暂无分享,去创建一个
M. L. Martins | Silvio C. Ferreira | Leticia R Paiva | Christopher Binny | Silvio C Ferreira | Marcelo L Martins | C. Binny | L. Paiva
[1] F. Khuri,et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] S. Swisher,et al. Redirecting adaptive immunity against foreign antigens to tumors for cancer therapy , 2007, Cancer biology & therapy.
[3] R. Jain,et al. Cancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumors. , 2008, Cancer research.
[4] R. Weinberg,et al. The Biology of Cancer , 2006 .
[5] M. Gulley,et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[6] M. L. Martins,et al. Reaction-diffusion model for the growth of avascular tumor. , 2001, Physical review. E, Statistical, nonlinear, and soft matter physics.
[7] M. L. Martins,et al. Morphology transitions induced by chemotherapy in carcinomas in situ. , 2002, Physical review. E, Statistical, nonlinear, and soft matter physics.
[8] M. Coffey,et al. Reovirus therapy of tumors with activated Ras pathway. , 1998, Science.
[9] M. L. Martins,et al. Multiscale models for the growth of avascular tumors , 2007 .
[10] M. Magnusson,et al. An oncolytic adenovirus redirected with a tumor-specific T-cell receptor. , 2007, Cancer research.
[11] M. Coffey,et al. Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial , 2008, Gene Therapy.
[12] R. Hill,et al. E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models , 2003, Nature Biotechnology.
[13] Y. Chen,et al. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. , 1999, Cancer research.
[14] S K Baird,et al. Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer , 2008, Oncogene.
[15] E. Galanis,et al. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress , 2007, Nature Clinical Practice Oncology.
[16] L. Wein,et al. Analysis of a three-way race between tumor growth, a replication-competent virus and an immune response , 2004, Bulletin of mathematical biology.
[17] S. Russell,et al. Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumor in an ovarian cancer xenograft model , 2006, Cancer Gene Therapy.
[18] J. Foloppe,et al. Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus , 2008, Gene Therapy.
[19] L. Eisenlohr,et al. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma , 1999, Cancer Gene Therapy.
[20] W. Rom,et al. Human matrix metalloproteinase-8 gene delivery increases the oncolytic activity of a replicating adenovirus. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[21] D. Wodarz,et al. Viruses as antitumor weapons: defining conditions for tumor remission. , 2001, Cancer research.
[22] G. Milton,et al. The limited role of attenuated smallpox virus in the management of advanced malignant melanoma. , 1966, The Australian and New Zealand journal of surgery.
[23] Lawrence M Wein,et al. Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. , 2003, Cancer research.
[24] Vasilis Ntziachristos,et al. Shedding light onto live molecular targets , 2003, Nature Medicine.
[25] G. Barber,et al. Genetically Engineered Vesicular Stomatitis Virus in Gene Therapy: Application for Treatment of Malignant Disease , 2002, Journal of Virology.
[26] J. Bell,et al. Recent progress in the battle between oncolytic viruses and tumours , 2005, Nature Reviews Cancer.
[27] M. L. Martins,et al. Fighting cancer with viruses , 2005 .
[28] E. Chiocca,et al. Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector. , 1998, Annals of surgery.
[29] 川島 健. Telomerase-specific replication-selective virotherapy for human cancer , 2004 .
[30] F. Khuri,et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. , 2000, Cancer research.